3-(1,1,2,2-四氟乙氧基)苯甲醛 | 35295-35-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 3-(1,1,2,2-四氟乙氧基)苯甲醛
• 中文别名: 3-(1,2,2-四氟乙氧基)苯甲醛；间四氟乙氧基苯甲醛
• 英文名称: 3-(1,1,2,2-Tetrafluoroethoxy)-benzaldehyde
• 英文别名: 3-(1,1,2,2-Tetrafluoroethoxy)benzaldehyde
• CAS: 35295-35-3
• 化学式: C₉H₆F₄O₂
• mdl: MFCD00039574
• 分子量: 222.139
• InChiKey: LAFOZKQZOGJYKC-UHFFFAOYSA-N

物化性质

• 沸点：
  95-97°C 9mm
• 密度：
  1.393 g/mL at 25 °C (lit.)
• 闪点：
  216 °F

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  6

安全信息

• 危险等级：
  TOXIC
• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2913000090
• 安全说明：
  S26,S37/39
• 危险标志：
  GHS07
• 危险性描述：
  H315,H319,H335
• 危险性防范说明：
  P261,P305 + P351 + P338

SDS

Name:	3-(1 1 2 2-Tetrafluoroethoxy)benzaldehyde 95% Material Safety Data Sheet
Synonym:	Benzaldehyde, 3-(1,1,2,2-tetrafluoroethoxy)-; m-(1,1,2,2-Tetrafluoroethoxy)benzaldehyd
CAS:	35295-35-3

Section 1 - Chemical Product MSDS Name:3-(1 1 2 2-Tetrafluoroethoxy)benzaldehyde 95% Material Safety Data Sheet
Synonym:Benzaldehyde, 3-(1,1,2,2-tetrafluoroethoxy)-; m-(1,1,2,2-Tetrafluoroethoxy)benzaldehyd

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
35295-35-3	3-(1,1,2,2-Tetrafluoroethoxy)benzaldeh	95	252-496-5

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea. The toxicological properties of this substance have not been fully investigated.
Inhalation:
Causes respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. Causes irritation of the mucous membrane.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Wash clothing before reuse.
Ingestion:
If victim is conscious and alert, give 2-4 cupfuls of milk or water.
Never give anything by mouth to an unconscious person. Get medical aid.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up or absorb material, then place into a suitable clean, dry, closed container for disposal. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use only in a well-ventilated area. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 35295-35-3: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: colorless
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 95 - 97 deg C @ 8.00mm Hg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not applicable.
Flash Point: 102 deg C ( 215.60 deg F)
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density: 1.3930g/cm3
Molecular Formula: C9H6F4O2
Molecular Weight: 222.14

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, excess heat.
Incompatibilities with Other Materials:
Strong oxidizing agents, strong bases.
Hazardous Decomposition Products:
Carbon monoxide, irritating and toxic fumes and gases, carbon dioxide, hydrogen fluoride gas.
Hazardous Polymerization: Will not occur.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 35295-35-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-(1,1,2,2-Tetrafluoroethoxy)benzaldehyde - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 35295-35-3: No information available.
Canada
CAS# 35295-35-3 is listed on Canada's NDSL List.
CAS# 35295-35-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 35295-35-3 is listed on the TSCA inventory.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-(1,1,2,2-四氟乙氧基)苯甲醛 在 三乙酰氧基硼氢化钠 、 溶剂黄146 、 三乙胺 、 ytterbium(III) triflate 作用下， 以 二氯甲烷 、 1,2-二氯乙烷 为溶剂， 反应 32.0h， 生成 N-(3-bromophenyl)-N-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-3,3,3-trifluoropropyl]-3-(1,1,2,2-tetrafluoroethoxy)benzenemethanamine
  参考文献：
  名称：

  发现了一种简单的胆固醇酯转移蛋白的皮摩尔抑制剂。

  摘要：

  描述了一种新颖的取代的N- [3-（1,1,2,2-四氟乙氧基）苄基] -N-（3-苯氧基苯基）-三氟-3-氨基-2-对戊醇的系列化合物，该化合物可有效和可逆地抑制胆固醇基酯转移蛋白（CETP）。从初始铅1开始，将各种取代基引入3-苯氧基苯胺基团，以优化相对活性，以抑制CETP介导的[3H]-胆固醇酯从HDL供体颗粒向缓冲液或缓冲液中的HDL供体颗粒转移至LDL受体颗粒。人血清。缓冲液分析中较好的抑制剂聚集在苯氧基在3、4或5位被取代的化合物之间。通常，相对于1，小的亲脂性烷基，卤代烷基，卤代烷氧基和卤素部分会提高效力 而含有给电子或氢键接受基团的类似物显示出较低的效力。具有极性或强吸电子基团的化合物也显示出较低的效能。用简单的脂族或环烷基醚以及碱性杂芳基氧基取代1中的苯氧基环会导致效能降低。从较好的化合物中，制备了具有代表性的4a-i系列手性纯R（+）对映体，并从中鉴定出4-氯-3-乙基

  DOI：

  10.1021/jm020528+

文献信息

• Substituted N, N-disubstituted diamino compounds useful for inhibiting cholesteryl ester transfer protein activity
  申请人：——

  公开号：US20020120011A1

  公开（公告）日：2002-08-29

  The invention relates to substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamine compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Preferred tertiary-heteroalkylamine compounds are substituted N,N-disubstituted diamines. A preferred specific N,N-disubstituted diamine is the compound: 1

  这项发明涉及替代多环芳基和杂环芳基的三级杂烷基胺化合物，可用作胆固醇酯转移蛋白（CETP；血浆脂质转移蛋白-I）的抑制剂，以及用于治疗动脉粥样硬化和其他冠状动脉疾病的化合物、组合物和方法。首选的三级杂烷基胺化合物是取代的N,N-二取代二胺。首选的具体N,N-二取代二胺化合物是：1
• LXR AGONISTS AND USES THEREOF
  申请人：Martinez Eduardo J.

  公开号：US20170066791A1

  公开（公告）日：2017-03-09

  This invention features compounds that modulate the activity of liver X receptors, pharmaceutical compositions including the compounds of the invention, and methods of utilizing those compositions for modulating the activity of liver X receptors in the treatment of cancer.

  这项发明涉及调节肝X受体活性的化合物，包括该发明的化合物的药物组合物，以及利用这些组合物调节肝X受体活性治疗癌症的方法。
• Synthesis, molecular properties, anti-inflammatory and anticancer activities of novel 3-hydroxyflavone derivatives
  作者：Mansour Znati、Claire Bordes、Valérian Forquet、Pierre Lantéri、Hichem Ben Jannet、Jalloul Bouajila

  DOI：10.1016/j.bioorg.2019.103009

  日期：2019.8

  cytotoxic activity against the human cell lines HCT-116 (Human colon carcinoma), IGROV-1 and OVCAR-3 (human ovarian carcinoma). It has been found that the derivatives 25, 37 and 45 were the most actives against HCT-116 (IC50 = 8.0, 9.0 and 9.0 μM, respectively) and against IGROV-1 (IC50 = 2.4, 5.0 and 6.0 μM, respectively). The derivatives 14 and 21 exhibited the higher anti-inflammatory activity at 100 μM

  按照克莱森-施密特的方法，一步合成了一系列新的3-羟基黄酮（1-46），然后进行了阿尔加-弗林-奥马达达反应（AFO）。合成的类黄酮通过1 H NMR，13 C NMR和DCI-HRMS进行表征。在体外测试所有合成的化合物对人细胞系HCT-116（人类结肠癌），IGROV-1和OVCAR-3（人类卵巢癌）的15-脂氧合酶抑制作用和细胞毒活性。已经发现，衍生物25、37和45对HCT-116（分别为IC50 ＝ 8.0、9.0和9.0μM）和对IGROV-1（分别为IC50 ＝ 2.4、5.0和6.0μM）最具活性。衍生物14和21在100μM下表现出更高的抗炎活性，PI值分别为76.50和72.70％。分子描述是通过DFT计算完成的，药物相似性和生物活性分数。结果表明，某些化合物与LiPInski的五个规则线性相关，显示出良好的药物相似性和针对药物靶标的生物活性得分。
• FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF
  申请人：Sakai Nozomu

  公开号：US20090137595A1

  公开（公告）日：2009-05-28

  The present invention provides a fused heterocyclic derivative having a potent kinase inhibitory activity and use thereof. A compound represented by the formula (I): wherein each symbol is as defined in the specification, except a particular compound, or a salt thereof, and a pharmaceutical agent containing the compound or a prodrug thereof, which is a kinase (VEGFR, VEGFR2, PDGFR, Raf) inhibitor, an angiogenesis inhibitor, an agent for the prophylaxis or treatment of cancer, a cancer growth inhibitor or a cancer metastasis suppressor.

  本发明提供了一种具有强大激酶抑制活性的融合杂环衍生物及其用途。 一种由以下式（I）表示的化合物： 其中除了特定化合物或其盐外，每个符号如规范中定义，以及含有该化合物或其前药的药用剂，该化合物是激酶（VEGFR、VEGFR2、PDGFR、Raf）抑制剂，血管生成抑制剂，用于癌症的预防或治疗的药剂，癌症生长抑制剂或癌症转移抑制剂。
• 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS
  申请人：Kuo Gee-Hong

  公开号：US20070265252A1

  公开（公告）日：2007-11-15

  The invention is directed to compounds of Formula (I) described herein useful as CETP inhibitors, compositions containing them, and methods of using them.

  本发明涉及式(I)化合物，所述化合物作为CETP抑制剂是有用的，包含它们的组合物以及使用它们的方法。